May 2014 FDA Recall Bystolic by Forest Pharmaceuticals Inc
D-1348-2014 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Forest Pharmaceuticals Inc on May 12, 2014 for the product Bystolic. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1348-2014

Reason for Recall
Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the product's shelf life.
Initiated
05-12-2014
Reported
05-28-2014
Quantity
21,875 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Forest Pharmaceuticals Inc
Nationwide and Puerto Rico
Bystolic (nebivolol), 20 mg/tablet, 30 tablets per bottle, Rx only, Licensed from Mylan Laboratories Inc., Under license from Janssen Pharmaceutica NV, Belgium, Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, Inc., St. Louis, MO, NDC 0456-1420-30

Batch or Lot Expiration Information

Lot# Lot: A287945, Exp: 08/2015